Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Nokia Corp — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Nokia Corp trades at $9.17 (market cap $54.54B). The key difference: Nokia Corp is far larger — about 6.1× Kymera Therapeutics Inc. Common Stock's market cap, and Nokia Corp pays a 1.66% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Nokia Corp for 65 Days on average.
| KYMR | NOK | |
|---|---|---|
Market Cap | $8.87B | $54.54B |
Volume | 779,107 | 76,721,489 |
Sector | Health | Technology |
52-Week High | $127.31 | $16.83 |
52-Week Low | $55.80 | $5.55 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $8.26B | $52.57B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nokia (NOK) trades at $9.40, down 5.05% in the last session, with a bearish technical signal. The company maintains a solid financial position with $19.89B in revenue and $651M net income for 2025, though profitability margins remain modest. Recent partnerships with Microsoft and ICEYE for AI and satellite communications highlight growth initiatives. Analyst consensus is bullish with a $17.50 price target, representing significant upside potential from current levels.
Nokia presents a compelling opportunity with strong analyst support and strategic positioning in 5G and AI infrastructure, though execution risks and competitive pressures persist. The stock's current valuation at 73x P/E appears stretched relative to 3.47% net margins, requiring careful monitoring of earnings growth to justify premium multiples. Near-term catalysts include Q3 2026 earnings and continued AI partnership developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
